{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T00:21:58Z","timestamp":1794270118843,"version":"4.9.0"},"reference-count":37,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.ijantimicag.2026.107960","type":"journal-article","created":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T23:45:24Z","timestamp":1786491924000},"page":"107960","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Intrapulmonary pharmacokinetics and safety of eravacycline in critically ill patients with HAP\/VAP caused by carbapenem-resistant Acinetobacter baumannii and Enterobacterales: A prospective study"],"prefix":"10.1016","volume":"67","author":[{"given":"Jingjing","family":"He","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nanyang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuancheng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingjing","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jufang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuehai","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiping","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yangyi","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5526-1502","authenticated-orcid":false,"given":"Xiaofen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2966-9149","authenticated-orcid":false,"given":"Jing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2026.107960_bib0001","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1007\/s00134-020-06036-z","article-title":"Diagnosis of ventilator-associated pneumonia in critically ill adult patients-a systematic review and meta-analysis","volume":"46","author":"Fernando","year":"2020","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.ijantimicag.2026.107960_bib0002","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.1001\/jama.2009.1754","article-title":"International study of the prevalence and outcomes of infection in intensive care units","volume":"302","author":"Vincent","year":"2009","journal-title":"Jama"},{"key":"10.1016\/j.ijantimicag.2026.107960_bib0003","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1186\/s13054-020-03091-2","article-title":"Update of the treatment of nosocomial pneumonia in the ICU","volume":"24","author":"Zaragoza","year":"2020","journal-title":"Crit Care"},{"key":"10.1016\/j.ijantimicag.2026.107960_bib0004","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00582-2017","volume":"50","author":"Torres","year":"2017","journal-title":"Eur Respir J"},{"key":"10.1016\/j.ijantimicag.2026.107960_bib0005","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/S1473-3099(25)00118-5","article-title":"The WHO Bacterial Priority Pathogens List 2024: a prioritisation study to guide research, development, and public health strategies against antimicrobial resistance","volume":"25","author":"Sati","year":"2025","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ijantimicag.2026.107960_bib0006","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciae403","article-title":"Infectious Diseases Society of America 2024 guidance on the treatment of antimicrobial-resistant gram-negative infections","author":"Tamma","year":"2024","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2026.107960_bib0007","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2021.106487","article-title":"Intrapulmonary pharmacokinetics of high doses of tigecycline in patients with ventilator-associated pneumonia","volume":"59","author":"Dimopoulos","year":"2022","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2026.107960_bib0008","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1080\/17425255.2018.1434142","article-title":"Pharmacokinetic drug evaluation of avibactam + ceftazidime for the treatment of hospital-acquired pneumonia","volume":"14","author":"Falcone","year":"2018","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.ijantimicag.2026.107960_bib0009","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02319-16","article-title":"Nephrotoxicity of polymyxins: is there any difference between colistimethate and polymyxin B?","volume":"61","author":"Zavascki","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2026.107960_bib0010","doi-asserted-by":"crossref","first-page":"e61","DOI":"10.1093\/cid\/ciw353","article-title":"Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society","volume":"63","author":"Kalil","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2026.107960_bib0011","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02497-17","article-title":"Pneumonia and renal replacement therapy are risk factors for Ceftazidime-avibactam treatment failures and resistance among patients with carbapenem-resistant Enterobacteriaceae infections","volume":"62","author":"Shields","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2026.107960_bib0012","doi-asserted-by":"crossref","DOI":"10.1128\/aac.01991-21","article-title":"Analysis of the clinical pipeline of treatments for drug-resistant bacterial infections: despite progress, more action is needed","volume":"66","author":"Butler","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2026.107960_bib0013","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1007\/s40265-016-0545-8","article-title":"Review of Eravacycline, a novel fluorocycline antibacterial agent","volume":"76","author":"Zhanel","year":"2016","journal-title":"Drugs"},{"key":"10.1016\/j.ijantimicag.2026.107960_bib0014","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1186\/s12866-025-03914-8","article-title":"Investigation of the in vitro antimicrobial activity of eravacycline alone and in combination with various antibiotics against MDR Acinetobacter baumanni strains","volume":"25","author":"Ataman","year":"2025","journal-title":"BMC Microbiol"},{"key":"10.1016\/j.ijantimicag.2026.107960_bib0015","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1128\/AAC.02036-13","article-title":"Phase I, open-label, safety and pharmacokinetic study to assess bronchopulmonary disposition of intravenous eravacycline in healthy men and women","volume":"58","author":"Connors","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2026.107960_bib0016","doi-asserted-by":"crossref","DOI":"10.1128\/aac.01065-24","article-title":"Population pharmacokinetics and pulmonary modeling of eravacycline and the determination of microbiological breakpoint and cutoff of PK\/PD","volume":"69","author":"Ji","year":"2025","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2026.107960_bib0017","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1080\/14787210.2024.2397663","article-title":"Efficacy and safety of eravacycline (ERV) in treating infections caused by gram-negative pathogens: a systematic review and meta-analysis","volume":"22","author":"Chen","year":"2024","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.1016\/j.ijantimicag.2026.107960_bib0018","doi-asserted-by":"crossref","first-page":"2738","DOI":"10.1093\/jac\/dkab238","article-title":"Eravacycline pharmacokinetics in a critically ill patient receiving venovenous extracorporeal membrane oxygenation and continuous venovenous haemodialysis","volume":"76","author":"Igneri","year":"2021","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2026.107960_bib0019","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2025.107603","article-title":"Population pharmacokinetics\/pharmacodynamics of eravacycline in patients with complicated intra-abdominal infections and community acquired bacterial pneumonia: support for a fixed-dose treatment regimen","volume":"66","author":"Chen","year":"2025","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2026.107960_bib0020","doi-asserted-by":"crossref","first-page":"S521","DOI":"10.1093\/ofid\/ofx163.1359","article-title":"Pharmacokinetics (PK) of eravacycline in subjects with renal or hepatic impairment compared with healthy subjects","volume":"4","author":"Horn","year":"2017","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.ijantimicag.2026.107960_bib0021","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.ijantimicag.2014.12.020","article-title":"Augmented renal clearance and therapeutic monitoring of \u03b2-lactams","volume":"45","author":"Udy","year":"2015","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2026.107960_bib0022","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics13122085","article-title":"The development of third-generation tetracycline antibiotics and new perspectives","volume":"13","author":"Rusu","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ijantimicag.2026.107960_bib0023","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1007\/s00134-020-06050-1","article-title":"Antimicrobial therapeutic drug monitoring in critically ill adult patients: a position paper","volume":"46","author":"Abdul-Aziz","year":"2020","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.ijantimicag.2026.107960_bib0024","article-title":"Dahyot-Fizelier C. Optimization of antimicrobial therapy in critically ill patients, what clinicians and searchers must know","volume":"44","author":"Roger","year":"2025","journal-title":"Anaesth Crit Care Pain Med"},{"key":"10.1016\/j.ijantimicag.2026.107960_bib0025","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40262-012-0018-5","article-title":"The clinical relevance of plasma protein binding changes","volume":"52","author":"Roberts","year":"2013","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.ijantimicag.2026.107960_bib0026","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciaa1271","article-title":"The relationship between drug concentration in tuberculosis lesions, epithelial lining fluid, and clinical outcomes","volume":"73","author":"Pasipanodya","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2026.107960_bib0027","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1164\/rccm.202306-0974OC","article-title":"Antimicrobial drug penetration is enhanced by lung tissue inflammation and injury","volume":"209","author":"Geilen","year":"2024","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.ijantimicag.2026.107960_bib0028","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1093\/jac\/dkp301","article-title":"Comparison of tigecycline penetration into the epithelial lining fluid of infected and uninfected murine lungs","volume":"64","author":"Crandon","year":"2009","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2026.107960_bib0029","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1093\/cid\/ciy1029","article-title":"IGNITE4: results of a phase 3, randomized, multicenter, prospective trial of Eravacycline vs Meropenem in the treatment of complicated intraabdominal infections","volume":"69","author":"Solomkin","year":"2019","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2026.107960_bib0030","doi-asserted-by":"crossref","first-page":"S354","DOI":"10.1086\/431676","article-title":"The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections: analysis of pooled clinical trial data","volume":"41","author":"Babinchak","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2026.107960_bib0031","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01174-18","article-title":"Randomized, double-blind, placebo-controlled studies of the safety and pharmacokinetics of single and multiple ascending doses of eravacycline","volume":"62","author":"Newman","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2026.107960_bib0032","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofac492.1259","article-title":"1430. Eravacycline associated hypofibrinogenemia during treatment of M.abscessus","volume":"9","author":"Rausch","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.ijantimicag.2026.107960_bib0033","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofac591","article-title":"Eravacycline associated hypofibrinogenemia: a case series of transplant patients with mycobacterium abscessus infections and review of literature","volume":"9","author":"Rausch","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.ijantimicag.2026.107960_bib0034","doi-asserted-by":"crossref","DOI":"10.1093\/jac\/dkag030","article-title":"Impact of eravacycline on fibrinogen","volume":"81","author":"Stevenson","year":"2026","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2026.107960_bib0035","doi-asserted-by":"crossref","first-page":"3480","DOI":"10.1093\/jac\/dkaa372","article-title":"Emergence of tigecycline- and eravacycline-resistant tet(X4)-producing Enterobacteriaceae in the gut microbiota of healthy Singaporeans","volume":"75","author":"Ding","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2026.107960_bib0036","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.jgar.2022.05.020","article-title":"Synergism of eravacycline combined with other antimicrobial agents against carbapenem-resistant enterobacteriaceae and acinetobacter baumannii","volume":"30","author":"Li","year":"2022","journal-title":"J Glob Antimicrob Resist"},{"key":"10.1016\/j.ijantimicag.2026.107960_bib0037","article-title":"Evaluating the efficacy of eravacycline and omadacycline against extensively drug-resistant acinetobacter baumannii patient isolates","volume":"11","author":"Deolankar","year":"2022","journal-title":"Antibiotics (Basel)"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857926002475?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857926002475?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T23:36:12Z","timestamp":1794267372000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857926002475"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":37,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S0924857926002475"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2026.107960","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Intrapulmonary pharmacokinetics and safety of eravacycline in critically ill patients with HAP\/VAP caused by carbapenem-resistant Acinetobacter baumannii and Enterobacterales: A prospective study","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2026.107960","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd and International Society of Antimicrobial Chemotherapy. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"107960"}}